Bentley Pharmaceuticals Begins Trading on the New York Stock Exchange - Shares continue trading under the ticker symbol 'BNT' - EXETER, N.H., May 12 /PRNewswire-FirstCall/ -- Bentley Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on advanced drug-delivery technologies, which also manufactures and markets generic and branded products in Europe, today announced that its common stock began trading on the New York Stock Exchange (NYSE) as James R. Murphy, Chairman, President and CEO of Bentley rang The Opening Bell(TM). Shares of the Company's common stock will continue trading under the ticker symbol, "BNT." Mr. Murphy, commented, "Bentley's listing on the prestigious NYSE marks a significant milestone in our growth and development and represents another step in our ongoing commitment to delivering value to our shareholders. The NYSE listing will provide greater visibility and access to a wider investor base. We are honored to join the family of NYSE-listed companies and look forward to continued growth and development on the NYSE," concluded Mr. Murphy. Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures and markets a growing portfolio of generic and branded pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiaries, Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar; and manufactures and sells active pharmaceutical ingredients through its subsidiary, Bentley API. Copies of Bentley Pharmaceuticals' press releases and other information may be obtained through Bentley's web site at http://www.bentleypharm.com/. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward looking statements, including without limitation, statements regarding the effects of the listing of our Common Stock on the New York Stock Exchange including our visibility to additional investors and an increase in stockholder base. These forward- looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, risks associated with expanding generic and branded drug operations, changes in third-party reimbursement and government mandates which impact pharmaceutical pricing, actions of third parties, including stock exchange regulatory authorities and investors, and other uncertainties detailed in Bentley's most recent Annual Report on Form 10-K and its other subsequent periodic reports filed with the Securities and Exchange Commission. Bentley cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Bentley undertakes no obligation to update or revise the statements, except as may be required by law. DATASOURCE: Bentley Pharmaceuticals, Inc. CONTACT: Michael D. Price, Vice President and Chief Financial Officer of Bentley Pharmaceuticals, Inc., +1-603-658-6100; or Investors: Jonathan Birt, Lanie Marcus, or Media: Sean Leous, +1-212-850-5600, all of Financial Dynamics Web site: http://www.bentleypharm.com/

Copyright